Protective effects of amifostine on ischemia-reperfusion injury of rat kidneys

Objectives: Amifostine is a drug which can eliminate free oxygen radicals that appear in the body after radiation or chemotherapeutic agent exposure. It is used to decrease the renal toxicity of cisplatin. The aim of this study was to determine the role of amifostine in warm ischemia kidney model for prevention of ischemia/reperfusion injury and also to find out the mechanism for prevention from ischemia/reperfusion injury if such an effect does exist. Materials and Methods: Adult female rats (n = 40) that used in our study were divided into three groups. Group 1: Control (n = 8), group 2: Ischemia-control (n = 16), group 3: Amifostine treated (n = 16). The effect of amifostine on ischemia/reperfusion injury investigated in rat kidneys. Results: At the 7th day, blood urea nitrogen level was statistically significantly higher in ischemia-control group than all groups (P = 0.001) and mean serum creatinine levels were found to be the highest in ischemia-control group (P = 0.091). Mean malondialdehyde levels in left kidneys removed on the 7th day were not significantly different (P = 0.105) at all three groups. Between ischemia-control group and amifostine group, there was a significant difference in reduced glutathione (GSH) levels (P = 0.001). In amifostine group, grade 4 necrosis was not detected neither on 7th day nor day 0. Conclusion: Amifostine could decrease the degree and severity of necrosis after reperfusion. Amifostine could not prevent membrane lipid peroxidation caused by superoxide anion radicals in kidney but they could protect tissues from the harmful effects of ischemia/reperfusion injury by increasing the level of reduced GSH which is a well-known oxygen radical eliminator.

[1]  J. Pascual,et al.  Cardiotrophin-1 Administration Protects from Ischemia-Reperfusion Renal Injury and Inflammation , 2013, Transplantation.

[2]  J. Shim,et al.  Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety , 2013, Critical Care.

[3]  L. Gesualdo,et al.  Effects of ischemia-reperfusion injury in kidney transplantation: risk factors and early and long-term outcomes in a single center. , 2013, Transplantation proceedings.

[4]  J. Ijzermans,et al.  Protection Against Renal Ischemia-Reperfusion Injury by Ischemic Postconditioning , 2013, Transplantation.

[5]  Lauren J Radvansky,et al.  Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  F. Rodríguez,et al.  Reactive oxygen and nitrogen species in the renal ischemia/reperfusion injury. , 2013, Current pharmaceutical design.

[7]  David W. Smith,et al.  Haemodynamic influences on kidney oxygenation: Clinical implications of integrative physiology , 2013, Clinical and experimental pharmacology & physiology.

[8]  E. Çopuroğlu,et al.  The effects of apelin on mesenteric ischemia and reperfusion damage in an experimental rat model. , 2012, Balkan medical journal.

[9]  K. Goa,et al.  Amifostine , 2012, Drugs.

[10]  F. Ozpuyan,et al.  Protective effect of l-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats , 2011, Medical oncology.

[11]  A. Dürrbach,et al.  Renoprotective potency of amifostine in rat renal ischaemia-reperfusion. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  C. Georgiou,et al.  Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits , 2009, Journal of cardiothoracic surgery.

[13]  Benjamin R. Lee,et al.  Real-time quantitation of renal ischemia using targeted microbubbles: in-vivo measurement of P-selectin expression. , 2009, Journal of endourology.

[14]  W. Rowiński,et al.  Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. , 2008, Transplantation proceedings.

[15]  P. Kuppusamy,et al.  Role of oxygen in postischemic myocardial injury. , 2007, Antioxidants & redox signaling.

[16]  E. Krause,et al.  Cardioprotective potency of the radical scavenger S-2-(3 aminopropylamino) ethylphosphorothioic acid in the post-ischaemic rat heart , 1995, Molecular and Cellular Biochemistry.

[17]  R. Capizzi Clinical status and optimal use of amifostine. , 1999, Oncology.

[18]  F. Giles,et al.  The potential of amifostine: from cytoprotectant to therapeutic agent. , 1999, Haematologica.

[19]  P. Jablonski,et al.  AN EXPERIMENTAL MODEL FOR ASSESSMENT OF RENAL RECOVERY FROM WARM ISCHEMIA , 1983, Transplantation.